Yahoo Finance

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction ...

Modern Vision Centers Highlights EVO ICL as a Lens-Based Alternative to LASIK for Patients in West Des Moines and Beyond

West Des Moines, Iowa - February 25, 2026 - PRESSADVANTAGE - Modern Vision Centers is drawing national attention to the ...
Morningstar

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction New FDA expansion of U.S. age indication extends EVO ICL use for patients ...
Business Wire

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

In parallel with these market trends, long-term clinical evidence for EVO ICL continues to strengthen. In the FDA clinical trial, 629 eyes were followed for three years, demonstrating a strong safety ...